Small and Mid-Sized European Companies (SMECs) has produced significant new blockbuster drugs that have been launched in Europe or progressed into late-stage development. There is a need for the product originators to maximize the potential of these products and analyze the importance of timely partnerships to launch their products in US. This feature explains the deals made with the SMECs and suggestions for SMECs to tap the lucrative US market and in making licensing deals.